Soft Interferometric Nanostrain Sensor Reveals Solid‐Liquid Interfacial Tension Oscillation Amplified by Competitive Adsorption

Why It Matters

The technology offers label‑free, real‑time insight into protein‑surface interactions, crucial for designing hemocompatible biomaterials and reducing infection risks in medical devices.

Key Takeaways

• Sensor resolves tension changes <0.25 mN m⁻¹
• Detects high‑frequency oscillations during adsorption
• Oscillation amplitude rises with competitive adsorption
• γSL decreases with higher FBS concentration
• Enables label‑free, real‑time protein mixture monitoring

Pulse Analysis

Protein adsorption governs the performance of medical implants, diagnostic chips, and drug‑delivery platforms, yet traditional techniques rely on fluorescent tags or bulk measurements that miss rapid, competitive events. By exploiting the elastocapillary effect—where a nanometer‑scale deformation of a soft substrate reflects changes in surface energy—the new interferometric nanostrain sensor translates minute interfacial tension shifts into optical signals. This label‑free approach preserves native protein behavior, delivering sub‑nanometer deformation data and tension resolution finer than 0.25 mN m⁻¹, far surpassing conventional tensiometry.

The sensor’s real‑time readout reveals a previously unobserved high‑frequency, low‑amplitude oscillation superimposed on the classic Langmuir adsorption curve. Experiments with fetal bovine serum demonstrate that as multiple protein species vie for the solid surface, the oscillation’s amplitude grows, indicating that competitive adsorption dynamically modulates interfacial tension. This insight bridges molecular‑scale adsorption events with macroscopic surface energy, offering a quantitative handle on how complex protein mixtures alter material wettability and fouling propensity.

For industry, the ability to monitor unlabeled protein interactions instantly opens pathways to engineer surfaces with tailored hemocompatibility, anti‑biofouling, or targeted cell adhesion properties. Manufacturers of catheters, stents, and biosensors can now validate surface treatments under realistic biological conditions without disruptive labeling. Moreover, the sensor’s ensemble‑averaging capability could accelerate formulation screening in biopharma, where protein‑protein competition impacts formulation stability. As the technology scales, it may become a standard analytical tool for both academic research and quality‑control labs seeking deeper, faster understanding of protein‑surface dynamics.